Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Plasmodium falciparum resistance against artemisinins has been confirmed in South-East Asia and it is expressed phenotypically as a slow rate of parasite clearance. Nonetheless, it is not known whether the problem exist in Tanzania. This study assessed parasite clearance time and time to recurrent infection following treatment with Artemether/Lumefantrine (AL) among children with uncomplicated malaria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.

NCT02089841

Plasmodium Falciparum Malaria

COMPLETED PHASE4

Treatment of Uncomplicated Childhood Malaria in Tanzania by Artemether+Lumefantrine - Efficacy and Genotyping

NCT00336375

Malaria

COMPLETED PHASE4

Effectiveness of Artemether-Lumefantrine for Malaria Treatment of Children at Community Level in Tanzania

NCT00454961

Malaria

COMPLETED PHASE4

Efficacy And Safety Of AL For The Treatment Of Uncomplicated Falciparum Malaria In Mainland Tanzania

NCT03387631

Uncomplicated Malaria

COMPLETED

Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar

NCT03764527

Plasmodium Falciparum Malaria

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Artemether/Lumefantrine (AL) has been in wide scale use in Tanzania since 2007 as first line treatment for uncomplicated falciparum malaria. Nonetheless, reports of confirmed resistance against Artemisinin derivatives expressed phenotypically as prolonged parasite clearance have emerged from South-East Asia (SEA), signifying reduced parasites susceptibility to the otherwise rapidly acting artemisinins. Prolonged clearance is associated with an increase in day 28 treatment failure, gametocytes carriage and transmission of resistance. Nonetheless, no detailed study has been done in East Africa to assess parasite clearance time following treatment with Artemisinin based combination therapies (ACTs).

In order to evaluate time to parasite clearance following treatment with AL, we conducted a detailed clinical trial with twenty blood sampling time points prior, during and after treatment. Detailed sampling allowed us to assess parasite clearance, and selection of Plasmodium falciparum multidrug resistance (Pfmdr) 1 N86Y and Plasmodium falciparum chloroquine resistance transporter (Pfcrt) K76T genes between different time points and its association with parasite clearance and recurrence. Furthermore, as a sensitive tool and an ideal early warning system, nested polymerase chain reaction (PCR) was used to assess parasite clearance and compare it with microscopic findings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Instantaneous Clearance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Artemether/lumefantrine

Artemether/lumefantrine tablets, 6 doses, for 3 days

Dosage:

1. tablet for body weight between 5-14.9 Kilograms.
2. tablets for body weight between 15-24.9 Kilograms.
3. tablets for body weight between 25-34.9 Kilograms.

Group Type ACTIVE_COMPARATOR

Artemether/lumefantrine

Intervention Type DRUG

Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artemether/lumefantrine

Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Coartem

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 6-120 months
* Presence of asexual P. falciparum parasitaemia of 2000-200 000/μL
* No general danger signs or severe malaria present
* Hemoglobin ≥5 g/dL
* History of fever within 24 hours or axillary temperature ≥ 37.5 degree Celsius
* No other cause of fever is detectable
* No severe malnutrition
* Guardian/patient has consented

Exclusion Criteria

* general danger signs or signs of severe falciparum malaria
* severe malnutrition
* febrile condition due to diseases other than malaria
* regular medication which might interfere with antimalarial pharmacokinetics
* contraindications to any medicine being used

Minimum Eligible Age

6 Months

Maximum Eligible Age

120 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No